MA53184A - Anticorps anti-ox40 et leurs utilisations - Google Patents

Anticorps anti-ox40 et leurs utilisations

Info

Publication number: MA53184A
Authority: MA; Morocco
Prior art keywords: antibodies
Prior art date: 2016-12-15

Application number

MA053184A

Other languages

English (en)

Inventor

Fiona A Harding

Original Assignee

Abbvie Biotherapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-12-15

Filing date

2017-12-15

Publication date

2021-05-26

2017-12-15 Application filed by Abbvie Biotherapeutics Inc filed Critical Abbvie Biotherapeutics Inc

2021-05-26 Publication of MA53184A publication Critical patent/MA53184A/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Cell Biology (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MA053184A 2016-12-15 2017-12-15 Anticorps anti-ox40 et leurs utilisations MA53184A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201662434761P	2016-12-15	2016-12-15

Publications (1)

Publication Number	Publication Date
MA53184A true MA53184A (fr)	2021-05-26

Family

ID=60937946

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA053184A MA53184A (fr)	2016-12-15	2017-12-15	Anticorps anti-ox40 et leurs utilisations

Country Status (37)

Country	Link
US (7)	US10556962B2 (fr)
EP (2)	EP3725809A1 (fr)
JP (2)	JP6772385B2 (fr)
KR (2)	KR102341926B1 (fr)
CN (1)	CN110573527A (fr)
AR (1)	AR110526A1 (fr)
AU (1)	AU2017377036B2 (fr)
BR (2)	BR112019012328A2 (fr)
CA (1)	CA3045940A1 (fr)
CL (1)	CL2019001646A1 (fr)
CO (1)	CO2019007288A2 (fr)
CR (1)	CR20190330A (fr)
CY (1)	CY1123274T1 (fr)
DK (1)	DK3504242T3 (fr)
DO (1)	DOP2019000165A (fr)
EC (1)	ECSP19050049A (fr)
ES (1)	ES2813057T3 (fr)
HR (1)	HRP20201259T1 (fr)
HU (1)	HUE050399T2 (fr)
IL (1)	IL267070A (fr)
LT (1)	LT3504242T (fr)
MA (1)	MA53184A (fr)
MX (1)	MX2019007121A (fr)
MY (1)	MY198059A (fr)
PE (1)	PE20191403A1 (fr)
PH (1)	PH12019501357A1 (fr)
PL (1)	PL3504242T3 (fr)
PT (1)	PT3504242T (fr)
RS (1)	RS60664B1 (fr)
RU (1)	RU2753493C2 (fr)
SG (1)	SG10201914126RA (fr)
SI (1)	SI3504242T1 (fr)
SM (1)	SMT202000462T1 (fr)
TW (1)	TWI734879B (fr)
UA (1)	UA125041C2 (fr)
UY (1)	UY37523A (fr)
WO (1)	WO2018112346A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10556962B2 (en) *	2016-12-15	2020-02-11	Abbvie Biotherapeutics Inc.	Anti-OX40 antibodies and their uses
CA3066007A1 (fr) *	2017-06-09	2018-12-13	Glaxosmithkline Intellectual Property Development Limited	Polytherapie a l'aide d'un agoniste icos et d'un agoniste ox40 pour le traitement du cancer
US11242398B2 (en) *	2017-08-01	2022-02-08	Remd Biotherapeutics, Inc.	Anti-OX40 antibodies and methods of activating OX40
CN110790837A (zh) *	2018-08-02	2020-02-14	上海君实生物医药科技股份有限公司	抗btla抗体
WO2020119789A1 (fr) *	2018-12-14	2020-06-18	Wuxi Biologics (Shanghai) Co., Ltd.	Anticorps entièrement humains dirigés contre ox40, procédé de préparation correspondant, et utilisation associée
US12195545B2 (en)	2018-12-25	2025-01-14	Hanx Biopharmaceutics, Inc	Anti-OX40 monoclonal antibody and application thereof
CN110172090B (zh) *	2019-06-03	2020-04-03	中山标佳生物科技有限公司	Cd134单克隆抗体及其制备方法和癌症治疗中的应用
WO2021098851A1 (fr) *	2019-11-20	2021-05-27	Eucure (Beijing) Biopharma Co., Ltd	Anticorps bispécifiques anti-ctla4/ox40 et leurs utilisations
JOP20220151A1 (ar)	2019-12-17	2023-01-30	Amgen Inc	ناهض مستقبل إنترلوكين -2 / tnf المزدوج للاستخدام في العلاج
CN111303285B (zh) *	2019-12-27	2023-06-02	百力司康生物医药(杭州)有限公司	靶向ox40的抗体及其制备方法和应用
CN113045654A (zh) *	2019-12-27	2021-06-29	南开大学	抗ox40抗体及其用途
WO2021190431A1 (fr) *	2020-03-23	2021-09-30	百奥泰生物制药股份有限公司	Développement et application d'un activateur de cellules immunitaires
KR20230015328A (ko) *	2020-04-17	2023-01-31	허치슨 메디파르마 리미티드	항-ox40 항체 및 이의 용도
CN115461371B (zh) *	2020-06-30	2026-02-13	和铂医药(上海)有限责任公司	靶向ox40的抗体及其制备方法和应用
JP2023535074A (ja) *	2020-07-23	2023-08-15	ダインセラピューティクス，インコーポレーテッド	筋標的化複合体およびそれらの使用
CN111704671B (zh) *	2020-08-19	2020-11-24	广东赛尔生物科技有限公司	Ox40抗体及其在治疗癌症中的应用
CN112442121A (zh) *	2020-08-20	2021-03-05	山东兴瑞生物科技有限公司	Ox40抗体、其编码基因、及抗体的制备方法和在增强人体免疫功能中的应用
CN114106173A (zh) *	2020-08-26	2022-03-01	上海泰槿生物技术有限公司	抗ox40抗体、其药物组合物及应用
CN111763258B (zh) *	2020-09-01	2020-12-29	北京百奥赛图基因生物技术有限公司	抗ox40抗体及其用途
CN114515335A (zh) *	2020-11-19	2022-05-20	百奥泰生物制药股份有限公司	抗ox40抗体在治疗肿瘤或癌症中的应用
WO2022117572A2 (fr)	2020-12-02	2022-06-09	Oncurious Nv	Agoniste de ltbr utilisé pour la polythérapie contre le cancer
CN115260312B (zh) *	2021-04-30	2025-02-14	保诺科技（北京）有限公司	结合ox40的抗体或抗原结合片段
CN118121694A (zh) *	2022-12-01	2024-06-04	北京东方百泰生物科技股份有限公司	一种抗Siglec-15单克隆抗体的注射制剂

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4444887A (en)	1979-12-10	1984-04-24	Sloan-Kettering Institute	Process for making human antibody producing B-lymphocytes
US4634665A (en)	1980-02-25	1987-01-06	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en)	1980-02-25	1993-01-12	The Trustees Of Columbia University In The City Of New York	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4716111A (en)	1982-08-11	1987-12-29	Trustees Of Boston University	Process for producing human antibodies
US4510245A (en)	1982-11-18	1985-04-09	Chiron Corporation	Adenovirus promoter system
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5168062A (en)	1985-01-30	1992-12-01	University Of Iowa Research Foundation	Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en)	1985-12-18	1990-11-06	Ciba-Geigy Corporation	Deoxyribonucleic acid segment from a virus
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5413923A (en)	1989-07-25	1995-05-09	Cell Genesys, Inc.	Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
DK0463151T3 (da)	1990-01-12	1996-07-01	Cell Genesys Inc	Frembringelse af xenogene antistoffer
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69127627T2 (de)	1990-08-29	1998-02-19	Genpharm Int	Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
EP0519596B1 (fr)	1991-05-17	2005-02-23	Merck & Co. Inc.	Procédé pour réduire l'immunogénicité des domaines variables d'anticorps
ES2136092T3 (es)	1991-09-23	1999-11-16	Medical Res Council	Procedimientos para la produccion de anticuerpos humanizados.
ES2341666T3 (es)	1991-12-02	2010-06-24	Medimmune Limited	Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
KR100654645B1 (ko)	1995-04-27	2007-04-04	아브게닉스, 인크.	면역화된 제노마우스 유래의 인간 항체
AU2466895A (en)	1995-04-28	1996-11-18	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US5834597A (en)	1996-05-20	1998-11-10	Protein Design Labs, Inc.	Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US5916771A (en)	1996-10-11	1999-06-29	Abgenix, Inc.	Production of a multimeric protein by cell fusion method
JP4215172B2 (ja)	1996-12-03	2009-01-28	アムジェンフレモントインク．	複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
ES2172149T3 (es)	1997-04-14	2002-09-16	Micromet Ag	Nuevo metodo para la produccion de receptores de antigeno anti-humano y sus usos.
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
US6312700B1 (en)	1998-02-24	2001-11-06	Andrew D. Weinberg	Method for enhancing an antigen specific immune response with OX-40L
AP1261A (en)	1998-02-24	2004-03-19	Sisters Of Providence In Oregon	Composition containing an OX-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response.
ATE384792T1 (de)	1998-11-18	2008-02-15	Genentech Inc	Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern
US7829084B2 (en)	2001-01-17	2010-11-09	Trubion Pharmaceuticals, Inc.	Binding constructs and methods for use thereof
ES2295639T3 (es)	2002-06-13	2008-04-16	Crucell Holland B.V.	Agonistas del receptor ox40=(=cd134) y uso terapeutico descripcion.
US7217797B2 (en)	2002-10-15	2007-05-15	Pdl Biopharma, Inc.	Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2005123780A2 (fr)	2004-04-09	2005-12-29	Protein Design Labs, Inc.	Modification des affinites de liaison pour le fcrn ou de la demi-vie serique d'anticorps par mutagenese
TWI380996B (zh)	2004-09-17	2013-01-01	Hoffmann La Roche	抗ｏｘ４０ｌ抗體
EP1810035A4 (fr)	2004-11-10	2010-03-17	Macrogenics Inc	Fonction effectrice obtenue par creation par genie biologique de regions d'anticorps fc
TWI461436B (zh) *	2005-11-25	2014-11-21	Kyowa Hakko Kirin Co Ltd	人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
WO2007084559A2 (fr)	2006-01-13	2007-07-26	Board Of Regents, The University Of Texas System	Procedes en vue de traiter des pathologies en influencant la signalisation de recepteurs ox40 et procedes de criblage a haut debit en vue d’identifier des substances dans ce but
DK2242771T3 (da)	2007-12-14	2013-08-26	Pfizer	Bindingsmolekyler til den humane ox40-receptor
WO2013028231A1 (fr) *	2011-08-23	2013-02-28	Board Of Regents, The University Of Texas System	Anticorps anti-ox40 et leurs procédés d'utilisation
AP2013006771A0 (en)	2010-08-23	2013-03-31	Boards Of Regents The University Of Texas System	Anti-OX40 antibodies and methods of using the same
AU2014233528B2 (en)	2013-03-15	2019-02-28	Abbvie Biotherapeutics Inc.	Fc variants
DK2976361T3 (en) *	2013-03-18	2018-10-01	Biocerox Prod Bv	HUMANIZED ANTI-CD134- (0X40) ANTIBODIES AND APPLICATIONS THEREOF
CA2943834A1 (fr)	2014-03-31	2015-10-08	Genentech, Inc.	Therapie combinatoires comprenant des agents anti-angiogenese et des agonistes se liant a ox40
TW201619200A (zh)	2014-10-10	2016-06-01	麥迪紐有限責任公司	人類化抗－ｏｘ４０抗體及其用途
RU2017119231A (ru) *	2014-11-03	2018-12-06	Дженентек, Инк.	Способы и биомаркеры для прогнозирования эффективности и оценки лечения агонистом ох40
EA201792451A1 (ru) *	2015-05-07	2018-05-31	Агенус Инк.	Антитела к ox40 и способы их применения
CN114181309B (zh) *	2015-05-21	2024-07-30	鳄鱼生物科学公司	新型多肽
US20160347848A1 (en) *	2015-05-28	2016-12-01	Medimmune Limited	Therapeutic combinations and methods for treating neoplasia
EP3383914A4 (fr)	2015-12-02	2019-10-30	Agenus Inc.	Anticorps anti-ox40 et leurs procédés d'utilisation
US10556962B2 (en) *	2016-12-15	2020-02-11	Abbvie Biotherapeutics Inc.	Anti-OX40 antibodies and their uses

2017
- 2017-12-15 US US15/843,281 patent/US10556962B2/en active Active
- 2017-12-15 PT PT178260899T patent/PT3504242T/pt unknown
- 2017-12-15 HR HRP20201259TT patent/HRP20201259T1/hr unknown
- 2017-12-15 EP EP20173858.0A patent/EP3725809A1/fr not_active Withdrawn
- 2017-12-15 PL PL17826089T patent/PL3504242T3/pl unknown
- 2017-12-15 BR BR112019012328-8A patent/BR112019012328A2/pt not_active Application Discontinuation
- 2017-12-15 TW TW106144235A patent/TWI734879B/zh not_active IP Right Cessation
- 2017-12-15 AU AU2017377036A patent/AU2017377036B2/en not_active Ceased
- 2017-12-15 BR BR122020025629-0A patent/BR122020025629B1/pt active IP Right Grant
- 2017-12-15 SM SM20200462T patent/SMT202000462T1/it unknown
- 2017-12-15 LT LTEP17826089.9T patent/LT3504242T/lt unknown
- 2017-12-15 KR KR1020197020437A patent/KR102341926B1/ko not_active Expired - Fee Related
- 2017-12-15 MY MYPI2019003403A patent/MY198059A/en unknown
- 2017-12-15 UY UY0001037523A patent/UY37523A/es not_active Application Discontinuation
- 2017-12-15 MA MA053184A patent/MA53184A/fr unknown
- 2017-12-15 PE PE2019001249A patent/PE20191403A1/es unknown
- 2017-12-15 SI SI201730380T patent/SI3504242T1/sl unknown
- 2017-12-15 CR CR20190330A patent/CR20190330A/es unknown
- 2017-12-15 UA UAA201907981A patent/UA125041C2/uk unknown
- 2017-12-15 RS RS20200923A patent/RS60664B1/sr unknown
- 2017-12-15 JP JP2019531934A patent/JP6772385B2/ja not_active Expired - Fee Related
- 2017-12-15 WO PCT/US2017/066680 patent/WO2018112346A1/fr not_active Ceased
- 2017-12-15 DK DK17826089.9T patent/DK3504242T3/da active
- 2017-12-15 KR KR1020217041290A patent/KR20210157471A/ko not_active Withdrawn
- 2017-12-15 ES ES17826089T patent/ES2813057T3/es active Active
- 2017-12-15 SG SG10201914126RA patent/SG10201914126RA/en unknown
- 2017-12-15 HU HUE17826089A patent/HUE050399T2/hu unknown
- 2017-12-15 EP EP17826089.9A patent/EP3504242B1/fr active Active
- 2017-12-15 CA CA3045940A patent/CA3045940A1/fr not_active Abandoned
- 2017-12-15 AR ARP170103527A patent/AR110526A1/es unknown
- 2017-12-15 RU RU2019121895A patent/RU2753493C2/ru active
- 2017-12-15 MX MX2019007121A patent/MX2019007121A/es unknown
- 2017-12-15 CN CN201780086610.XA patent/CN110573527A/zh active Pending
2018
- 2018-02-28 US US15/908,221 patent/US10040864B2/en active Active
- 2018-08-06 US US16/056,042 patent/US20180346593A1/en not_active Abandoned
2019
- 2019-06-03 IL IL267070A patent/IL267070A/en unknown
- 2019-06-13 DO DO2019000165A patent/DOP2019000165A/es unknown
- 2019-06-14 CL CL2019001646A patent/CL2019001646A1/es unknown
- 2019-06-14 PH PH12019501357A patent/PH12019501357A1/en unknown
- 2019-07-08 CO CONC2019/0007288A patent/CO2019007288A2/es unknown
- 2019-07-12 EC ECSENADI201950049A patent/ECSP19050049A/es unknown
- 2019-10-24 US US16/663,131 patent/US10604584B2/en active Active
2020
- 2020-02-20 US US16/796,622 patent/US20200181282A1/en not_active Abandoned
- 2020-08-21 CY CY20201100785T patent/CY1123274T1/el unknown
- 2020-09-29 JP JP2020162944A patent/JP2021019603A/ja active Pending
- 2020-10-02 US US17/062,474 patent/US20210017289A1/en not_active Abandoned
2021
- 2021-12-23 US US17/560,664 patent/US20220112304A1/en not_active Abandoned

Also Published As

Publication number	Publication date
TWI734879B (zh)	2021-08-01
US20220112304A1 (en)	2022-04-14
JP2021019603A (ja)	2021-02-18
US10556962B2 (en)	2020-02-11
WO2018112346A1 (fr)	2018-06-21
PL3504242T3 (pl)	2020-11-16
HRP20201259T1 (hr)	2020-11-13
UA125041C2 (uk)	2021-12-29
US10604584B2 (en)	2020-03-31
SI3504242T1 (sl)	2020-10-30
RS60664B1 (sr)	2020-09-30
SMT202000462T1 (it)	2020-09-10
AR110526A1 (es)	2019-04-10
RU2753493C2 (ru)	2021-08-17
US20200048363A1 (en)	2020-02-13
KR20210157471A (ko)	2021-12-28
JP2020504101A (ja)	2020-02-06
CN110573527A (zh)	2019-12-13
CY1123274T1 (el)	2021-12-31
EP3725809A1 (fr)	2020-10-21
LT3504242T (lt)	2020-09-10
RU2019121895A (ru)	2021-01-15
US20180194855A1 (en)	2018-07-12
US20200181282A1 (en)	2020-06-11
MY198059A (en)	2023-07-31
JP6772385B2 (ja)	2020-10-21
PT3504242T (pt)	2020-08-26
KR20190092552A (ko)	2019-08-07
CR20190330A (es)	2019-12-19
US20210017289A1 (en)	2021-01-21
MX2019007121A (es)	2020-02-05
TW201825520A (zh)	2018-07-16
AU2017377036B2 (en)	2022-06-23
DOP2019000165A (es)	2019-07-15
US20180171023A1 (en)	2018-06-21
UY37523A (es)	2018-07-31
PE20191403A1 (es)	2019-10-04
DK3504242T3 (da)	2020-08-17
BR112019012328A2 (pt)	2019-11-19
RU2019121895A3 (fr)	2021-02-15
CL2019001646A1 (es)	2019-08-23
US20180346593A1 (en)	2018-12-06
HUE050399T2 (hu)	2020-12-28
PH12019501357A1 (en)	2020-01-20
ES2813057T3 (es)	2021-03-22
SG10201914126RA (en)	2020-02-27
EP3504242B1 (fr)	2020-06-24
IL267070A (en)	2019-08-29
KR102341926B1 (ko)	2021-12-23
US10040864B2 (en)	2018-08-07
CO2019007288A2 (es)	2019-08-20
BR122020025629B1 (pt)	2022-05-31
CA3045940A1 (fr)	2018-06-21
AU2017377036A1 (en)	2019-07-11
EP3504242A1 (fr)	2019-07-03
ECSP19050049A (es)	2019-07-31

Publication	Publication Date	Title
FR25C1020I1 (fr)	2025-08-01	Anticorps thérapeutiques et leurs utilisations
MA53184A (fr)	2021-05-26	Anticorps anti-ox40 et leurs utilisations
EP3625263A4 (fr)	2021-05-05	Anticorps anti-galectine-9 et leurs utilisations
EP3426686A4 (fr)	2019-11-06	Anticorps anti-pacap humanisés et leurs utilisations
EP3504243A4 (fr)	2020-03-11	Anticorps anti-tim-3 et leurs utilisations
MA49687A (fr)	2020-06-03	Anticorps anti-ctla-4 et leurs utilisations
MA45235A (fr)	2019-04-17	Anticorps anti-c5 et leurs utilisations
EP3383916A4 (fr)	2019-09-11	Anticorps anti-cd73 et leurs utilisations
MA46708A (fr)	2021-05-05	Anticorps anti-pd1 et leurs utilisations
MA46704A (fr)	2019-09-11	Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
MA47789A (fr)	2020-01-22	Anticorps anti-phf-tau et leurs utilisations
MA49537A (fr)	2020-05-13	Anticorps anti-lag3 et leurs utilisations
EP3328895A4 (fr)	2019-08-21	Anticorps anti-pd-l1 et leurs utilisations
EP3389702A4 (fr)	2019-08-14	Anticorps anti-lag-3 et leurs utilisations
MA49683A (fr)	2020-06-03	Anticorps anti-cd8 et leurs utilisations
EP3661965A4 (fr)	2022-07-13	Anticorps anti-cd47 et leurs utilisations
EP3377102C0 (fr)	2023-08-09	Anticorps anti-pd-1 et leurs utilisations thérapeutiques
MA45125A (fr)	2021-06-02	Anticorps anti-alpha-synucléine et leurs utilisations
MA49886A (fr)	2020-06-24	Anticorps anti-par2 et leurs utilisations
EP3283516A4 (fr)	2019-03-06	Anticorps anti-pacap et leurs utilisations
MA42935A (fr)	2018-08-01	Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations
EP3383904A4 (fr)	2019-12-04	Anticorps ctla-4 et leurs utilisations
EP3400243A4 (fr)	2019-09-25	Anticorps anti-pd-l1 et utilisations associées
EP3356416A4 (fr)	2019-04-10	Anticorps anti-pd-1 et ses utilisations
EP3645563A4 (fr)	2021-03-17	Anticorps anti-fam19a5 et leurs utilisations